Type I interferons and IL-12: convergenc
β
AdrianaβA. Byrnes; Xiaojing Ma; Peter Cuomo; Kiwon Park; Larry Wahl; StanleyβF.
π
Article
π
2001
π
John Wiley and Sons
π
English
β 195 KB
Therapeutic use of type I IFN (IFN- Β§ / g ) has become common. Many of the diverse diseases targeted are marked by pathogenetic abnormalities in cell-mediated immunity (CMI), these cellular immune responses either causing injury to the host, lacking sufficient vigor for virus or tumor clearance, or